2/16/05

```
=> s l1
SAMPLE SEARCH INITIATED 12:58:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      5 TO ITERATE

100.0% PROCESSED       5 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 12:58:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    115 TO ITERATE

100.0% PROCESSED     115 ITERATIONS                               18 ANSWERS
SEARCH TIME: 00.00.01

L3           18 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               161.33     161.54

FILE 'CAPLUS' ENTERED AT 12:58:30 ON 16 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 16 Feb 2005  VOL 142 ISS 8
FILE LAST UPDATED: 15 Feb 2005  (20050215/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4            1 L3

=> d abs fbib hitstr
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I



II

AB The invention relates to compds. I and their (in)organic acid salts, solvates and/or hydrates [wherein: X = NR2 or CHR2; Ar = Ph mono- or disubstituted by halo or C1-3 alkyl; R1 = Cl, Br, C1-3 alkyl, or CF3; R2 = CR3R4CONR5R6; R3, R4 = Me, Et, n-Pr, Bu; or CR3R4 forms C3-6 cycloalkyl; R5, R6 = H, C1-3 alkyl; or NR5R6 = azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, or perhydroazepin-1-yl]. The compds. exhibit a high affinity and high selectivity with respect to human NK1 receptors of substance P. The compds. are also orally active and demonstrate passage of the blood-brain barrier. The invention also relates to a method for production of I, intermediates useful in their production, pharmaceutical compns. containing them, and their use in the production of medicaments to treat all pathologies involving substance P and human NK1 receptors. Syntheses of 22 examples and a variety of intermediates are described. For instance, amidation of 3,5-dimethylphenylacetic acid with the (-)-isomer of 3-(3,4-dichlorophenyl)-3-(2-hydroxyethyl)piperidine, followed by Swern oxidation of the alc. to an aldehyde, and reductive amination of this with 2-(piperidin-4-yl)isobutyramide-HCl, gave title compound (-)-II.HCl.H2O. Compds. I inhibited binding of substance P to human NK1 receptors in vitro with a Ki of approx. 10-11M, vs. 10-8M for NK2 receptors and 10-7 for NK3 receptors.

AN 2000:573786 CAPLUS

DN 133:177101

TI 1-[2-[1-(Phenylacetyl)-3-phenyl-3-piperidyl]ethyl]piperidine derivatives, method for the production thereof, and pharmaceutical compositions containing them as NK1 receptor antagonists

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IN Ducoux, Jean Philippe; Emonds-Alt, Xavier; Gueule, Patrick; Proietto, Vincenzo

PA Sanofi-Synthelabo, Fr.

SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000047572	A1	20000817	WO 2000-FR284	20000208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
FR 2789389	A1	20000811	FR 1999-1593	19990210
FR 2789389	B3	20010309		
FR 2789390	A1	20000811	FR 1999-4429	19990407
FR 2789390	B3	20010309		
			FR 1999-1593	A 19990210
CA 2360894	AA	20000817	CA 2000-2360894	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
BR 2000008067	A	20011106	BR 2000-8067	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
EP 1150970	A1	20011107	EP 2000-903744	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
TR 200102331	T2	20020321	TR 2001-200102331	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
NZ 513053	A	20021025	NZ 2000-513053	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
JP 2002536442	T2	20021029	JP 2000-598492	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
EE 200100417	A	20021216	EE 2001-417	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

			WO 2000-FR284	W 20000208
AU 763716	B2	20030731	AU 2000-25531	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
RU 2220956	C2	20040110	RU 2001-121989	20000208
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
ZA 2001005829	A	20020716	ZA 2001-5829	20010716
			FR 1999-1593	A 19990210
HR 2001000566	A1	20020831	HR 2001-566	20010726
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
NO 2001003878	A	20011010	NO 2001-3878	20010808
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
BG 105794	A	20020531	BG 2001-105794	20010808
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
US 6642233	B1	20031104	US 2001-913106	20010809
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
US 2004072840	A1	20040415	US 2003-663124	20030916
			FR 1999-1593	A 19990210
			FR 1999-4429	A 19990407
			WO 2000-FR284	W 20000208
			US 2001-913106	A3 20010809

OS MARPAT 133:177101

IT **288378-97-2P 288378-98-3P 288379-04-4P**
288379-06-6P 288379-08-8P 288379-10-2P
288379-14-6P 288379-22-6P 288379-26-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [[(phenylacetyl)phenylpiperidyl]ethyl]piperidine derivs. as NK1 receptor antagonists)

RN 288378-97-2 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-dimethylphenyl)acetyl]-3-piperidinyl]ethyl]-α,α-dimethyl-, dihydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RN 288378-98-3 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-dimethylphenyl)acetyl]-3-piperidinyl]ethyl]-N,N,α,α-tetramethyl-, dihydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



●2 HCl

RN 288379-04-4 CAPLUS

CN Cyclohexanecarboxamide, 1-[4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-dimethylphenyl)acetyl]-3-piperidinyl]ethyl]-1-piperazinyl]-, dihydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RN 288379-06-6 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-dichlorophenyl)acetyl]-3-piperidinyl]ethyl]-α,α-dimethyl-, dihydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



●2 HCl

RN 288379-08-8 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-dichlorophenyl)acetyl]-3-piperidinyl]ethyl]-N,N,α,α-tetramethyl-, dihydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RN 288379-22-6 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-diethylphenyl)acetyl]-3-piperidinyl]ethyl]-α,α-dimethyl-, dihydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



●2 HCl

RN 288379-26-0 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[1-[(3,5-dichlorophenyl)acetyl]-3-(3,4-dimethylphenyl)-3-piperidinyl]ethyl]-α,α-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RN 288379-10-2 CAPLUS
CN Cyclohexanecarboxamide, 1-[4-[2-[3-(3,4-dichlorophenyl)-1-[(3,5-dichlorophenyl]acetyl]-3-piperidinyl]ethyl]-1-piperazinyl]-, dihydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



●2 HCl

RN 288379-14-6 CAPLUS
CN Cyclohexanecarboxamide, 1-[4-[2-[1-[[3,5-bis(trifluoromethyl)phenyl]acetyl]-3-(3,4-dichlorophenyl)-3-piperidinyl]ethyl]-1-piperazinyl]-, dihydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

2/16/05

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.84	167.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

STN INTERNATIONAL LOGOFF AT 12:59:46 ON 16 FEB 2005